Manejo práctico de fugas periprótesis en pacientes rehabilitados con prótesis fonatorias tipo Provox®2 tras laringectomía total

Friedlander, Eviatar; Martínez, Paloma Pinacho; Serafini, D; Martin-Oviedo, Carlos; Guirado, Tomás Martinez; Yurrita, Bartolomé Scola

doi:10.1016/j.otorri.2015.12.004

Cited by 8 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its full text was evaluated according to the proposed methodology, after which 9 manuscripts were excluded due to being in a language other than English or Spanish, [19][20][21][22] did not evaluate tissue augmentation treatment, [23][24][25][26] or use the tissue augmentation treatment for other purposes. 27 The final result was 15 articles included (Table 1): 7 retrospective case series, [28][29][30][31][32][33][34] 1 prospective case series, 35 2 case series in which the time sequence is not specified, 36,37 and 5 case reports. [38][39][40][41][42]…”

Section: Resultsmentioning

confidence: 99%

“…The first treatment option for this type of leak is usually conservative methods: changing the size of the prosthesis, placing a silicone reinforcement collar, removing the VP and placing a nasogastric tube to allow contraction of the fistula, suturing in a tobacco pouch, placing a VP specifically designed for the treatment of these leaks, etc. Within this group of treatment, and without being the only option or excluding it from being combined with other therapies, 10,31 there is peri‐fistula injection with different substances that increase the volume of the surrounding tissue and reduce the diameter of the fistula. Since its first description in 1988, 42 numerous studies have been carried out with different substances for the same purpose, with no single material showing evidence of clear superiority to the rest.…”

Section: Discussionmentioning

confidence: 99%

“…Based on this early level of evidence, the therapy appears to be an effective, safe and long‐lasting option in nearly 89% of cases. It can also be used in conjunction with other conservative treatments in a concomitant manner, and a greater benefit and leak‐free duration can be obtained 31 …”

Section: Discussionmentioning

confidence: 99%

“…Of which, data could only be obtained for the quantitative analysis partially (Table 1). Out of the 196 injections (Table 2), 60 (30.6%) were with hyaluronic acid, [29][30][31][32]38,40,41 47 (24%) were with autologous fat, 28,35,36 40 (20.4%) with Cymetra, 33,34 29 (14.8%) with hydroxyapatite, 29,32,33 16 (8.2%) with Bioplastique ® , 37,39 3 (1.5%) with GM-CSF, 40 and 1 (0.5%) with Gax-collagen. 42 The mean age of the patients was 64.68 ± 7.95 years, with a male predominance (59.6%).…”

Section: Descriptive Analysismentioning

confidence: 99%

See 3 more Smart Citations

Tissue augmentation treatment for periprosthetic leakage in patients who have undergone a total laryngectomy: A systematic review

Mayo‐Yáñez

Ramos-Neble

Cabo-Varela

et al. 2023

Clinical Otolaryngology

View full text Add to dashboard Cite

Objectives: Tracheoesophageal puncture (TEP) is considered the gold standard for voice rehabilitation after total laryngectomy. One of the main causes of treatment failure, and a potentially serious complication, is the TEP enlargement and/or leakage around the voice prosthesis. The injection of biocompatible material to increase the volume of the puncture surrounding tissue has been studied as a popular option for conservative treatment of enlarged tracheoesophageal fistula. The aim of this paper was to perform a systematic review of the efficacy and safety of such treatment. Desingn: Search conducted in PubMed/MEDLINE, the Cochrane Library, Google Scholar, Scielo and Web of Science and through the meta-searcher Trip Database based on Preferred Reporting Items for a Systematic Review and Meta-analysis (PRISMA) statement.Miguel Mayo-Yáñez and Mercedes Díaz Ramos-Neble contributed equally to the study and have to be joined as co-senior authors.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Descriptive Analysismentioning

confidence: 99%

See 2 more Smart Citations

Tissue augmentation treatment for periprosthetic leakage in patients who have undergone a total laryngectomy: A systematic review

Mayo‐Yáñez

Ramos-Neble

Cabo-Varela

et al. 2023

Clinical Otolaryngology

View full text Add to dashboard Cite

show abstract

“…Over the last few years, different methods have appeared to solve this problem, most of them acting at the tracheal level and obtaining promising results although limited, and being necessary to perform some type of intervention on the patient. For this reason, in 2016 Provox® Vega™ XtraSeal™ (Atos Medical AB) appeared, which, based on these principles, incorporates a double flange on the pharyngeal side of the prosthesis in order to avoid these failures.…”

Section: Introductionmentioning

confidence: 99%

Use of double flange voice prosthesis for periprosthetic leakage in laryngectomised patients: A prospective case‐crossover study

Mayo‐Yáñez

Cabo-Varela

Suanzes

et al. 2020

Clinical Otolaryngology

View full text Add to dashboard Cite

Introduction Tracheoesophageal speech is considered the gold standard for rehabilitation following total laryngectomy. One of the main problems of voice prosthesis is the periprosthesis leakage. Provox Vega XtraSeal incorporates a double flange on the pharyngeal side of the prosthesis in order to avoid these failures. The aim of the study is to compare the device lifetime between the Provox Vega and Provox Vega XtraSeal and to examine possible related factors that influence their duration. Methods Prospective case‐crossover study in 20 laryngectomised patients with Provox Vega and periprothesis leakage to whom a Provox Vega XtraSeal was placed. Survival and possible factors that affect voice prosthesis were studied using Kaplan‐Meier curves and Cox Proportional Hazards Regression with Schoenfeld residuals to test the possible assumptions. Results A total of 230 prostheses were evaluated. The most frequent reason for replacement was due to an endoprosthesis leakage (n = 146, 67%) in both models. Mean lifetime of Provox Vega was 104.474 ± 7.29 days (CI 95% 90.19‐118.76) and of Provox XtraSeal was 176.76 ± 26.46 days (CI 95% 124.9‐228.61) (P = .012). Complementary treatment with radiotherapy demonstrated a higher device survival (P = .007). Discussion Provox XtraSeal seems to be effective reducing the number of changes due to periprosthetic leakage, thus increasing the survival of voice prosthesis.

show abstract

Analysis of Factors Affecting the Longevity of Voice Prosthesis Following Total Laryngectomy with a Review of Literature

Khwajamohiuddin

2017

Indian J Surg Oncol

View full text Add to dashboard Cite

Tracheoesophageal voice puncture (TEP) coupled with the use of voice prosthesis has been considered as the gold standard for speech rehabilitation in patients of advanced laryngeal/hypopharyngeal carcinomas, who have undergone a total laryngectomy with or without partial pharyngectomy. Although prosthetic voice rehabilitation is commonly practiced worldwide including India, there is a paucity of published Indian data, more so in the current era of organ conservation. This study included 60 laryngectomized patients with a prosthetic voice rehabilitation at a tertiary cancer center in South India between January 1, 2010 and December 31, 2013. Among the 60 patients, the primary site of cancer was the larynx in 43 patients and hypopharynx in the remaining 17. All patients had undergone a primary TEP insertion, 55 in the upfront setting and five in the salvage (post-radiation/chemo-radiation) setting. The ability to retain a successful trachea-esophageal speech on follow-up (median 15.5 months) in our series was around 82%. The mean device life of voice prosthesis in our patient cohort was 16 months. There was surprisingly no significant difference in the prosthesis device life on correlation with age, co-morbidities, habitat, literacy status, pre-operative tracheostomy, setting of surgery, and the extent of surgery. Our series has successfully demonstrated the safety and feasibility of using primary TEP coupled with the use of voice prosthesis for voice rehabilitation in properly selected and motivated patients of advanced laryngeal and hypopharyngeal carcinomas across all clinical settings. A mean device life of 16 months makes prosthetic voice rehabilitation, an attractive as well as a financially viable option for patients in a resource constrained setting.

show abstract

Manejo práctico de fugas periprótesis en pacientes rehabilitados con prótesis fonatorias tipo Provox®2 tras laringectomía total

Cited by 8 publications

References 10 publications

Tissue augmentation treatment for periprosthetic leakage in patients who have undergone a total laryngectomy: A systematic review

Tissue augmentation treatment for periprosthetic leakage in patients who have undergone a total laryngectomy: A systematic review

Use of double flange voice prosthesis for periprosthetic leakage in laryngectomised patients: A prospective case‐crossover study

Analysis of Factors Affecting the Longevity of Voice Prosthesis Following Total Laryngectomy with a Review of Literature

Contact Info

Product

Resources

About